Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.67 |
| ▸ | NPC1 | O15118 | 8/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4725005 | 0.88 | RAB9A (0.75) | RAB9ANPC1HDAC6TP53SMN1; SMN2 | |
| SCHEMBL4766696 | 0.84 | RAB9A (0.62) | RAB9ANPC1HDAC6TP53SMN1; SMN2 | |
| SCHEMBL2247503 | 0.83 | RAB9A (0.81) | RAB9ANPC1TP53SMN1; SMN2MAPT | |
| SCHEMBL2881289 | 0.82 | DRD2 (0.68) | RAB9ANPC1HDAC6SMN1; SMN2MAPT | |
| SCHEMBL2247920 | 0.81 | RAB9A (1.00) | RAB9ANPC1HDAC6TP53SMN1; SMN2 | |
| SCHEMBL4763542 | 0.80 | RAB9A (0.59) | RAB9ANPC1HDAC6TP53SMN1; SMN2 | |
| SCHEMBL2245364 | 0.79 | RAB9A (0.78) | RAB9ANPC1TP53SMN1; SMN2MAPT | |
| SCHEMBL14451614 | 0.79 | RAB9A (0.78) | RAB9ANPC1TP53SMN1; SMN2MAPT | |
| SCHEMBL4102373 | 0.79 | RAB9A (1.00) | RAB9ANPC1TP53SMN1; SMN2MAPT | |
| SCHEMBL14451616 | 0.79 | RAB9A (0.72) | RAB9ANPC1TP53SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979343-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | Pfizer Products Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007077490-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007077490-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2007-07-05 | — | — | US | disclosed |
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PDE12, PDE10A, PDE7A | RAB9A 334/4885NPC1 1991/4885HDAC6 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.